| Journal Article |
File Downloads |
Abstract Views |
| Last month |
3 months |
12 months |
Total |
Last month |
3 months |
12 months |
Total |
| "Crises" in medical malpractice insurance: Evidence of excessive price-cutting in the preceding soft market |
0 |
0 |
0 |
41 |
1 |
1 |
4 |
196 |
| A general model of the impact of absenteeism on employers and employees |
0 |
1 |
2 |
145 |
2 |
5 |
35 |
734 |
| A measure of malpractice: Medical injury, malpractice litigation and patient compensation, by Paul C. Weiler et al. Cambridge, MA: Harvard University Press, 1993, 178 pp., $29.95 cloth |
0 |
0 |
0 |
18 |
3 |
5 |
6 |
68 |
| Alternative Liability Regimes for Medical Injuries |
0 |
0 |
0 |
2 |
2 |
2 |
2 |
19 |
| At what price? |
0 |
0 |
0 |
0 |
2 |
3 |
3 |
4 |
| Comments on "The Assault on Managed Care: Vicarious Liability, ERISA Preemption, and Class Actions." |
0 |
0 |
0 |
0 |
0 |
0 |
3 |
297 |
| Contingent Fees for Personal Injury Litigation |
0 |
0 |
0 |
83 |
2 |
3 |
4 |
873 |
| Cross-national price differences for pharmaceuticals: how large, and why? |
0 |
0 |
1 |
322 |
5 |
8 |
17 |
755 |
| Differential Pricing of Pharmaceuticals: Theory, Evidence and Emerging Issues |
0 |
1 |
1 |
16 |
2 |
6 |
8 |
60 |
| Does Regulation Drive out Competition in Pharmaceutical Markets? |
0 |
2 |
5 |
37 |
5 |
10 |
22 |
1,196 |
| Dynamic competition in pharmaceuticals: cross-national evidence from new drug diffusion |
0 |
0 |
0 |
81 |
3 |
4 |
4 |
227 |
| Health Care Reform |
0 |
0 |
0 |
4 |
5 |
5 |
5 |
33 |
| Health Insurance and the Growth in Pharmaceutical Expenditures |
0 |
0 |
0 |
13 |
5 |
9 |
10 |
70 |
| Holdouts, Externalities, and the Single Owner: One More Salute to Ronald Coase: Comment |
0 |
0 |
0 |
4 |
4 |
6 |
7 |
254 |
| Hospital `profits': The effects of reimbursement policies |
0 |
0 |
0 |
38 |
2 |
3 |
4 |
144 |
| Liability and liability insurance for medical malpractice |
0 |
0 |
0 |
60 |
1 |
3 |
5 |
191 |
| Liability for Medical Malpractice |
0 |
0 |
0 |
199 |
2 |
5 |
9 |
689 |
| Medical negligence and the NHS: an economic analysis |
0 |
0 |
0 |
1 |
0 |
1 |
1 |
163 |
| Mergers and acquisitions in the pharmaceutical and biotech industries |
0 |
0 |
4 |
339 |
7 |
16 |
30 |
1,126 |
| Pharmaceutical Pricing in Emerging Markets: Effects of Income, Competition, and Procurement |
0 |
1 |
1 |
8 |
3 |
4 |
6 |
59 |
| Pharmacy Benefit Management: Are Reporting Requirements Pro- or Anticompetitive? |
0 |
0 |
0 |
10 |
1 |
1 |
3 |
39 |
| Price Cutting in Liability Insurance Markets |
0 |
0 |
1 |
111 |
4 |
6 |
9 |
484 |
| Price Discrimination for Pharmaceuticals: Welfare Effects in the US and the EU |
0 |
0 |
1 |
157 |
7 |
12 |
19 |
439 |
| Price, Financial Quality, and Capital Flows in Insurance Markets |
0 |
0 |
0 |
122 |
4 |
6 |
9 |
407 |
| Productivity in pharmaceutical-biotechnology R&D: the role of experience and alliances |
0 |
0 |
1 |
125 |
9 |
14 |
18 |
617 |
| Rate Regulation, Safety Incentives, and Loss Growth in Workers' Compensation Insurance |
0 |
0 |
0 |
78 |
4 |
5 |
8 |
660 |
| Reference Pricing of Pharmaceuticals for Medicare: Evidence from Germany, the Netherlands, and New Zealand |
0 |
0 |
0 |
77 |
3 |
4 |
10 |
464 |
| Regulation and its reform, by Stephen Breyer. Cambridge, MA: Harvard University Press, 1982, 472 pp. Price: $25.00 |
0 |
0 |
1 |
89 |
5 |
8 |
12 |
322 |
| Regulatory policy and practices: Regulating better and regulating less, by Fred Thomson and L.R. Jones. New York: Praeger Publishers, 1982, 253 pp. Price: $29.95 |
0 |
0 |
0 |
7 |
0 |
2 |
2 |
24 |
| Risk by choice: Regulating health and safety in the workplace, by W. Kip Viscusi. Cambridge, MA: Harvard University Press, 1983, 200 pp. Price: $18.50 |
0 |
0 |
0 |
6 |
0 |
2 |
3 |
56 |
| Separation of the redistributive and allocative functions of government: A public choice perspective |
0 |
0 |
2 |
70 |
1 |
2 |
7 |
470 |
| The Economic Implications of Public Disability Insurance in the United States |
0 |
0 |
0 |
46 |
1 |
1 |
3 |
208 |
| The Effects of Malpractice Litigation on Physicians' Fees and Incomes |
0 |
0 |
1 |
54 |
5 |
7 |
11 |
194 |
| The Frequency and Severity of Medical Malpractice Claims |
0 |
0 |
0 |
8 |
3 |
4 |
4 |
602 |
| The Political Economy of Workers' Compensation: Lessons for Product Liability |
0 |
0 |
0 |
10 |
2 |
4 |
4 |
69 |
| The Swedish patient compensation system: Myths and realities |
0 |
0 |
0 |
95 |
1 |
2 |
2 |
231 |
| The impact of price regulation on the launch delay of new drugs—evidence from twenty‐five major markets in the 1990s |
0 |
0 |
2 |
89 |
5 |
12 |
21 |
380 |
| Tort Liability: A Minefield for Managed Care? |
0 |
0 |
0 |
0 |
1 |
1 |
1 |
233 |
| Tort Reform: The Case of Medical Malpractice |
0 |
0 |
0 |
0 |
1 |
1 |
3 |
462 |
| Vaccine Supply: Effects of Regulation and Competition |
0 |
0 |
0 |
26 |
2 |
4 |
6 |
198 |
| Value‐Based Differential Pricing: Efficient Prices for Drugs in a Global Context |
0 |
0 |
1 |
22 |
6 |
6 |
9 |
154 |
| Welfare effects of supplementary insurance: a comment |
0 |
0 |
0 |
25 |
2 |
3 |
6 |
79 |
| Worker's Compensation Rate Regulation: How Price Controls Increase Costs |
0 |
0 |
1 |
2 |
2 |
4 |
6 |
437 |
| Total Journal Articles |
0 |
5 |
25 |
2,640 |
125 |
210 |
361 |
14,387 |
LogEc is hosted by the
Örebro University School of Business.